Literature DB >> 11602763

Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.

E Y Kim1, M A Winters, R M Kagan, T C Merigan.   

Abstract

Twenty-four of over 24,000 patients genotyped over the past 3 years were found to have human immunodeficiency virus (HIV) isolates that possess an insert in the protease gene. In this report, we evaluated the spectrum of protease gene insertion mutations in patient isolates and analyzed the effect of these various insertion mutations on viral phenotypes. The inserts were composed of 1, 2, 5, or 6 amino acids that mapped at or between codons 35 and 38, 17 and 18, 21 and 25, or 95 and 96. Reduced susceptibility to protease inhibitors was found in isolates which possess previously reported drug resistance mutations. Fitness assays, including replication and competition experiments, showed that most of the isolates with inserts grew somewhat better than their counterparts with a deletion of the insert. These experiments demonstrate that, rarely, insertion mutations can develop in the HIV type 1 protease gene, are no more resistant than any other sequences which have similar associated resistance mutations, and can provide a borderline advantage in replication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602763      PMCID: PMC114703          DOI: 10.1128/JVI.75.22.11227-11233.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Evidence for a unique mechanism of strand transfer from the transactivation response region of HIV-1.

Authors:  J K Kim; C Palaniappan; W Wu; P J Fay; R A Bambara
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

Review 3.  Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  D Boden; M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

4.  Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.

Authors:  R B Rose; C S Craik; R M Stroud
Journal:  Biochemistry       Date:  1998-02-24       Impact factor: 3.162

5.  Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

Authors:  P R Harrigan; S Bloor; B A Larder
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.

Authors:  M A Winters; J M Schapiro; J Lawrence; T C Merigan
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.

Authors:  M A Winters; R W Shafer; R A Jellinger; G Mamtora; T Gingeras; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

8.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Authors:  R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; R J Colonno; P F Lin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

9.  Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site.

Authors:  G P Harrison; M S Mayo; E Hunter; A M Lever
Journal:  Nucleic Acids Res       Date:  1998-07-15       Impact factor: 16.971

10.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

Authors:  M A Winters; K L Coolley; Y A Girard; D J Levee; H Hamdan; R W Shafer; D A Katzenstein; T C Merigan
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

View more
  5 in total

Review 1.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

2.  Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness.

Authors:  Terrence W Brann; Robin L Dewar; Min-Kan Jiang; Akram Shah; Kunio Nagashima; Julia A Metcalf; Judith Falloon; H Clifford Lane; Tomozumi Imamichi
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  A novel codon insert in protease of clade B HIV type 1.

Authors:  Parris S Jordan; Art Poon; Joseph Eron; Kathleen Squires; Caroline Ignacio; Douglas D Richman; Davey M Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

4.  Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.

Authors:  Milan Kozísek; Klára Grantz Sasková; Pavlína Rezácová; Jirí Brynda; Noortje M van Maarseveen; Dorien De Jong; Charles A Boucher; Ron M Kagan; Monique Nijhuis; Jan Konvalinka
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

5.  Actinomycin D induces high-level resistance to thymidine analogs in replication of human immunodeficiency virus type 1 by interfering with host cell thymidine kinase expression.

Authors:  Tomozumi Imamichi; Michael A Murphy; Joseph W Adelsberger; Jun Yang; Catherine M Watkins; Steve C Berg; Michael W Baseler; Richard A Lempicki; Jianhui Guo; Judith G Levin; H Clifford Lane
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.